Vaxcyte: Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vax

 

• VAX-24 Showed Robust Immune Responses Across all 24 Serotypes (ST) at All Doses, Confirming Prior Phase 2 Results in Adults Aged 50-64
• VAX-24 2.2mcg Dose Met Opsonophagocytic Activity (OPA) Response Non-Inferiority Criteria for 18 of 20 STs Common with Prevnar 20® (PCV20) and Superiority Criteria for the Four Additional VAX-24 STs
• VAX-24 2.2mcg Dose Showed Further Improvement in Overall Immune Responses vs. PCV20 Relative to Results from Phase 2 Study in Adults Aged 50-64
• Full Six-Month Safety Data from Both Adult Studies Demonstrated VAX-24 Safety and Tolerability Results Similar to PCV20 at All Doses Studied
• Prespecified Pooled Immunogenicity Analyses of Data from Both Adult Phase 2 Studies Showed the VAX-24 2.2mcg Dose Met OPA Non-Inferiority Criteria for All 20 STs Common with PCV20 and Superiority Criteria for the Four Additional VAX-24 STs
• VAX-24 Well-Positioned for Adult Phase 3 Program with Topline Data Anticipated in 2025
• Company to Host Webcast/Conference Call Today at 7:30 a.m. ET / 4:30 a.m. PT

Vaxcyte will hold a webcast and conference call today, April 17, 2023, at 7:30 a.m. ET / 4:30 a.m. PT to discuss these results. To participate in the conference call, please dial (800) 267-6316 (domestic) or (203) 518-9783 (international) and refer to conference ID PCVX0417. A live webcast of the conference call will also be available on the investor relations page of the Vaxcyte corporate website at www.vaxcyte.com. After the live webcast, the event will remain archived on the Vaxcyte website for 30 days.

https://www.biospace.com/article/releases/vaxcyte-reports-positive-data-from-phase-2-study-of-its-24-valent-pneumococcal-conjugate-vaccine-candidate-vax-24-in-adults-aged-65-and-older-and-full-six-month-safety-data-from-adult-phase-1-2-and-phase-2-studies/